Search clinical trials for: PRV111 (Cisplatin Transmucosal System)

Total 455 results

Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)

Non-Small Cell Lung Cancer

China, Spain, Canada, Israel, Italy, Japan, Korea, Republic of, Taiwan, Australia, Poland, Brazil, Turkey, Belgium, Singapore, Czechia, Romania, Germany, Russian Federation, Greece, Netherlands, Argentina, France, Hong Kong, Mexico, Ukr... and more
Polaris Group

Completed

Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC)

Mesothelioma

United States, United Kingdom, Taiwan, Australia, Italy
University of Michigan Rogel Cancer Center

Completed

Optimized Intensity Modulated Irradiation for Head and Neck Cancer

Head and Neck Cancer

United States
The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC (ANSWER)

Non-Small Cell Lung Cancer Stage IIIA

China
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC)

Head and Neck Squamous Cell Carcinoma

United States, France, Spain, Australia, Italy, Belgium, Hong Kong, Portugal, Poland, United Kingdom, Germany
Hoffmann-La Roche

Active, not recruiting

Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer (Match)

Carcinoma, Small Cell Lung

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

HPV-Associated Oropharyngeal Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Neck

United States
Medical University of South Carolina

Terminated

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Bladder Cancer

United States
NovoCure Ltd.

Completed

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Malignant Pleural Mesothelioma

Netherlands, Italy, Germany, Belgium, France, Poland, Spain
Aaron Moberly

Withdrawn

Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin

Ototoxicity | Malignant Neoplasm
University of Leicester

Unknown

Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma

Liver Cancer

France, United Kingdom, Netherlands, Ireland
Baylor College of Medicine

Active, not recruiting

Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer (BLAST)

Bladder Cancer

United States
NCIC Clinical Trials Group

Completed

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer

Breast Cancer

Canada
St. Jude Children's Research Hospital
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Brain and Central Nervous System Tumors

United States, Australia
AbbVie

Recruiting

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Small Cell Lung Cancer

United States, Israel, Japan
Genmab
BioNTech SE

Recruiting

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Malignant Solid Tumor

Japan
Eli Lilly and Company
Merck Sharp & Dohme LLC; Loxo Oncology, Inc.

Recruiting

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Biliary Tract Neoplasms

Canada, United States, Japan, Australia, France, Korea, Republic of
UNC Lineberger Comprehensive Cancer Center
AstraZeneca; Celgene

Active, not recruiting

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Carcinoma, Squamous Cell | Esophageal Cancer | Oral Cancer | Oropharynx Cancer | Larynx Cancer | Lip Cancer

United States
Beth Israel Deaconess Medical Center

Withdrawn

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
National Cancer Institute, Slovakia

Withdrawn

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Metastatic Breast Cancer

Slovakia
National Cancer Institute, Naples

Active, not recruiting

Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (V-CHANCE)

Squamous Cell Carcinoma of the Head and Neck

Italy
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
AstraZeneca

Recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)

Non-Small Cell Lung Cancer

China, United States, Chile, Vietnam, Thailand, Brazil, Bulgaria, Canada, Germany, India, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Turkey, Austria, Israel, Spain, Taiwan, Mexico, France, Italy, Peru, Switzerland, United...
Hyogo Medical University
Merck Sharp & Dohme LLC

Not yet recruiting

Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)

Malignant Pleural Mesothelioma

Japan
Wake Forest University Health Sciences
AstraZeneca; Atrium Health Levine Cancer Institute

Active, not recruiting

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Non Small Cell Lung Cancer | Lung Cancer Stage III | Lung Cancer Stage II

United States
Takeda

Active, not recruiting

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, France, Korea, Republic of, Israel, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Russian Federation, Switzerland, Austria, Japan, Denmark, Belgium, Greece, Netherlands, P... and more
Yale University
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Lung Cancer

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743)

Mesothelioma

Brazil, United States, China, Italy, Australia, Belgium, Chile, Colombia, France, Germany, Greece, Japan, Mexico, Netherlands, Poland, Romania, Russian Federation, South Africa, Switzerland, Turkey, United Kingdom
National Cancer Centre, Singapore
Bristol-Myers Squibb

Withdrawn

Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma

NK/T Cell Lymphoma

Singapore
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

Denmark, Italy, Australia, Korea, Republic of, Belgium, United States, Canada, Japan, United Kingdom, China, Brazil, France, Taiwan, Spain, Norway, Switzerland, Turkey, Poland, Germany, South Africa, Netherlands
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

Metastatic Non Small Cell Lung Cancer

Belgium, Australia, United States, Korea, Republic of, Spain, China, France, Thailand, Brazil, Japan, Germany, Romania, Hungary, Italy, Taiwan, Austria, Canada, Hong Kong, Argentina, Netherlands, Chile, Greece, Poland
University of Texas Southwestern Medical Center

Active, not recruiting

A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer (DARTBOARD)

Head and Neck Cancer

United States
Vilnius University
National Cancer Institute (NCI); Vilnius University Hospital Santaros Klinikos

Recruiting

PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer

Gastric Cancer | Peritoneal Carcinomatosis

Lithuania
Dana-Farber Cancer Institute
Massachusetts General Hospital; Pharmacia; Brigham and Women's Hospital

Completed

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Esophageal Cancer

United States
The Lymphoma Academic Research Organisation

Active, not recruiting

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance (LyMa101)

Mantle Cell Lymphoma

France
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

Metastatic Cancer | Liver Cancer

United States
Weill Medical College of Cornell University
Millennium Pharmaceuticals, Inc.

Completed

Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL

Non-Hodgkin's Lymphoma

United States
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Argentina, Hong Kong, Chile and more
Vanderbilt-Ingram Cancer Center
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Limited Stage Lung Small Cell Carcinoma | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung Cancer

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Non-Small Cell Lung Cancer

China
Marjolein Spiering
Millennium: The Takeda Oncology Company

Unknown

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Hodgkin Lymphoma | Relapse | Refractory

Netherlands, France, Denmark, United Kingdom
University of Maryland, Baltimore

Completed

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Boehringer Ingelheim

Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Lung Cancer, Non-squamous, Non-small Cell

Australia, Korea, Republic of, China, Japan, United States, Singapore
Gilead Sciences
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (EVOKE-02)

Non-small Cell Lung Cancer

United States, Spain, Italy, France, Australia, Hong Kong, Korea, Republic of, Malaysia, Taiwan, Germany, United Kingdom, Canada
Bristol-Myers Squibb

Withdrawn

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Amgen

Completed

A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (CHAMPION 2)

Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest... and other collaborators

Completed

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

Testicular Germ Cell Tumor | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

United States, Puerto Rico, Australia, Peru
German Society for Pediatric Oncology and Hematology...
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer | Nasopharynx Cancer | Nasopharyngeal Neoplasms

Germany
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States

Search clinical trials for: PRV111 (Cisplatin Transmucosal System)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations